A clinical laboratory technique used to identify common variations in DNA sequences, known as single nucleotide polymorphisms (SNPs), which can influence an individual’s unique capacity to synthesize, metabolize, or respond to specific hormones and pharmaceutical agents. This analysis is a cornerstone of personalized medicine in endocrinology. It provides predictive data on drug efficacy and potential adverse reaction profiles.
Origin
This practice is a product of advances in molecular genetics and genomics, with “polymorphism” derived from Greek poly (many) and morphe (form), referring to multiple forms of a gene. Its application in clinical practice emerged with the completion of the Human Genome Project, allowing for targeted assessment of metabolic and therapeutic response risk.
Mechanism
Specific SNPs in genes encoding enzymes, such as those in the cytochrome P450 family (e.g., CYP19A1 for aromatase) or steroid-metabolizing enzymes, can lead to altered enzyme activity. This variation directly impacts the speed and efficiency of hormone conversion and clearance, necessitating individualized dosing and therapeutic choices to optimize treatment efficacy and minimize adverse effects. Analyzing these polymorphisms provides critical insight into an individual’s unique endocrine landscape.
GINA compliance is secured through the architectural separation of an individual's neuro-endocrine-metabolic blueprint from all administrative and financial data streams.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.